JW Therapeutics’ $300 Million Initial Public Offering

Michael Patrini

Shearman & Sterling advised JW (Cayman) Therapeutics Co. Ltd. on the deal. JW (Cayman) Therapeutics Co. Ltd., a China-based cancer cell therapy developer, executed its primary…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

Author: Michael Patrini

…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here